Replies to post #100663 on Amarantus Bioscience Holdings Inc (AMBS)

[barcode27]

Part 2 of the 8-K:

On May 1, 2014, the Company entered into an asset purchase agreement (the “Provista APA”) with Provista Diagnostics, Inc., a Delaware Corporation (“Provista”) pursuant to which the Company purchased certain assets of Provista related to a fluorescently activated cell sorter (“FACS”), including all right, title and interest in the certain assets, equipment, software and technology related to FACS (altogether, the “Assets”).



As consideration for transfer of the Assets pursuant to the Provista APA, the Company shall, upon closing of the Provista APA, pay to Provista a one-time cash payment of $20,000.

I believe this is referring to a BD FACSCalibur machine like this one: www.bdbiosciences.com/instruments/facscalibur/

If AMBS is looking to commercialize LymPro with a CLIA partner (who would bring their own FACS capability), then why are they buying a machine of their own? Do they need to run additional proof-of-concept studies in-house? Do they want to run demos for potential future partners without having to lean on BD or a CLIA lab? Lots of possibilities here...